In a bipartisan spending agreement that was largely negotiated behind closed doors, Congress included a policy change with ...

Drug manufacturers participating in the Section 340B Drug Pricing Program now face a significant new litigation risk under ...

The closer we get to 2028, the more likely it is that the U.S. may settle for short-term solutions that do not meaningfully ...

On March 17, 2026, the Ninth Circuit issued a unanimous decision in United States ex rel. Adventist Health Sys. of W. v. AbbVie Inc. allowing a ...

Johnson & Johnson, Eli Lilly, Sanofi and Bristol Myers Squibb are suing the federal government over the future of their 340B drug rebate plans. The lawsuits reflect rising tensions among drugmakers, ...

The American Hospital Association argues new policies from Eli Lilly and Novo Nordisk requiring providers to submit more claims data on dispensed 340B drugs is onerous and unlawful.

The 340B program is criticized for generating revenue rather than solely aiding underinsured patients, impacting community providers and Medicare patients. Pharmaceutical companies face challenges ...

Add Yahoo as a preferred source to see more of our stories on Google. Photo: Shopify Partners / Burst (The Center Square) – Hospitals and clinics in Michigan participating in a federal drug discount ...

The 340B Drug Discount Program was designed to help safety-net providers make drugs available to low-income patients and earn revenue. Drug manufacturers have put restrictions on which pharmacies ...

The drug discount program is under scrutiny on a variety of fronts ...

Unexpected windfall or fragile safety net? Affluent communities or vulnerable poor? Welfare check or supplemental provider program? Making sense of the latest 340B program study published by the ...

(The Center Square) – Hospitals and clinics in Michigan participating in a federal drug discount program are marking up medications and shifting costs onto public employee health plans, according to a ...